Contract research organizations (CROs) are playing a pivotal role in new drug development as pharmaceutical companies face rising R&D costs and leaner in-house research departments. Strategic partnerships between drug developers and CROs can dramatically decrease a drug’s time to market - according to the Tufts Center for the Study of Drug Development, clinical trials conducted by CROs are completed, on average, 30 percent faster than those conducted in- house. Ed Amat is the Executive Vice President of Global Sales & Marketing at MPI Research and is well versed in the CRO partnership arena. We sat down with Ed and asked him to share his insight on CRO partnerships in today’s market, and explain the company’s technology and how Sponsors can make the most of their collaborative approach.